Biomarkers for hcv treatment response

Details Biomarkers for hcv treatment response Biomarkers for hcv treatment response

C - Chemistry, Metallurgy

12

Q

C12Q 1/68 (2006.01) C12Q 1/70 (2006.01)

Patent

CA 2745284

The present invention is based on the discovery that in patients infected with Hepatitis C Virus Genotype 1 (HCV-1) or Genotype 4 (HCV-4), a beneficial response to a treatment that includes interferon alpha, ribavirin and a HCV polymerase inhibitor could be predicted if the patient's HCV RNA level becomes undetectable in as short as two weeks post treatment.

La présente invention est basée sur la découverte que, chez des patients infectés par le virus de l'hépatite C génotype 1 (VHC-1) ou génotype 4 (VHC-4), une réponse bénéfique à un traitement qui comprend l'interféron alpha, la ribavirine et un inhibiteur de polymérase de VHC peut être prédite si le taux d'ARN de VHC du patient devient indétectable en seulement deux semaines après le traitement.

Affiliated with

Also associated with

Rating

Biomarkers for hcv treatment response does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Biomarkers for hcv treatment response, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Biomarkers for hcv treatment response will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1757333